Post by i-Pharm GxP

US Life Sciences manufacturing is undergoing a structural reset, and 2025 was the year it accelerated. In the latest edition of our GxP Insights newsletter, we break down the $370B+ surge in US-based manufacturing investment and what it signals for pharma, biotech and medtech as reshoring shifts from headlines to execution. We cover: → Why 2025 became the year of “Build It Here” → The companies leading the charge, including Eli Lilly, AstraZeneca, J&J, Novartis, Roche, BMS, Gilead and more → Where new capacity is landing across the US, and why hubs and emerging regions are competing harder than ever → The real constraints ahead: talent scarcity, time-to-build, cost and operational readiness → Our 2026 outlook --- Want more insights like this? ✅ Subscribe to GxP Insights for monthly deep-dives across Medical Devices, Biologics, Cell & Gene Therapy, and Sterile/Aseptic Manufacturing ✅ Follow i-Pharm GxP for perspectives on regulation, talent demand and life sciences market shifts #lifesciences #manufacturing #reshoring #biopharma #medtech #GxP #biologics #cellandgenetherapy #pharma #careers #talent #newsletter #industryinsights